Skip to main content
Premium Trial:

Request an Annual Quote

Selvita Spins Out Bioinformatics Business Into Subsidiary Ardigen

NEW YORK (GenomeWeb) – Drug discovery firm Selvita today said that it has formed a subsidiary called Ardigen to take over its bioinformatics business.

Ardigen's big data integration and analysis services business and custom application development operations will expand Selvita's bioinformatics services, Selvita said. Ardigen will form a new business unit focused on biological and clinical data analysis in genomics, transcriptomics, proteomics, metabolomics, and immunomics, and will also create a business unit around personalized medicine products and services.

Ardigen Co-founder Janusz Homa is the firm's CEO. He is the co-founder and former CEO of software company Software Mind. Sebastian Kwasny is Ardigen's vice president of operations. He is also a member of Selvita's management board.

Ardigen currently has 20 employees. It also has taken over Selvita's collaborations with Abbott Informatics, Microsoft, Oracle, IBM, and Qiagen, Selvita said.

"Starting Ardigen is our response to the vast amount of information on the mechanisms, progression, and treatment outcomes of various life-threatening disorders and related new therapies, a challenge which doctors currently face without adequate and affordable solutions," Pawel Przewiezlikowski, CEO of Krakow, Poland-based Selvita, said in a statement.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.